<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04728334</url>
  </required_header>
  <id_info>
    <org_study_id>AK117-102</org_study_id>
    <nct_id>NCT04728334</nct_id>
  </id_info>
  <brief_title>Phase 1, Dose Escalation and Dose Expansion Study of AK117, a CD47 Antibody</brief_title>
  <official_title>A Multicenter, Phase 1, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 in Subjects With Advanced Solid Tumors or Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akeso</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akeso</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open label, single arm, Phase 1，dose escalation and dose expansion&#xD;
      study designed to evaluate the safety, tolerability, pharmacodynamics, PK, immunogenicity,&#xD;
      and preliminary antitumor activity of AK117 administered intravenously to adult subjects with&#xD;
      relapsed/refractory advanced or metastatic solid tumors or lymphomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study comprises a dose escalation phase and a dose expansion phase. The phases will be&#xD;
      conducted sequentially. Approximately 162 subjects will be enrolled in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 27, 2021</start_date>
  <completion_date type="Anticipated">January 27, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 27, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs)</measure>
    <time_frame>From the time of informed consent signed through 30 days after the last dose of AK117</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with a Dose Limiting Toxicity (DLT)</measure>
    <time_frame>During the first 21 days</time_frame>
    <description>DLTs will be assessed during the first 21 days of treatment for dose-escalation phase and are defined as toxicities that meet pre-defined severity criteria, and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>ORR defined as the proportion of subjects who achieves a best overall response of CR or PR, assessed by Investigator per RECIST Version 1.1 for solid tumor or the Lugano 2014 Classification for lymphoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The DCR is defined as the proportion of subjects with CR, PR, or SD .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of AK117</measure>
    <time_frame>From first dose of AK117 through to 30 days after last dose of AK117</time_frame>
    <description>The endpoints for assessment of PK of AK104 include serum concentrations of AK117 at different timepoints after AK117 administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum observed concentration (Cmin) of AK117 at steady state</measure>
    <time_frame>From first dose of AK117 through to 30 days after last dose of AK117</time_frame>
    <description>The endpoints for assessment of PK of AK104 include serum concentrations of AK117 at different timepoints after AK117 administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who develop detectable anti-drug antibodies (ADAs)</measure>
    <time_frame>From first dose of AK117 through to 30 days after last dose of AK117</time_frame>
    <description>The immunogenicity of AK117 will be assessed by summarizing the number of subjects who develop detectable antidrug antibodies (ADAs).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Neoplasms Malignant</condition>
  <arm_group>
    <arm_group_label>AK117 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AK117 monotherapy intravenous (IV) infusion - Weekly doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK117</intervention_name>
    <description>An intravenous (IV) infusion of AK117 as monotherapy. All subjects will receive 4 weekly infusions (Days 1, 8, 15, and 22) of AK117 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal</description>
    <arm_group_label>AK117 monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All Subjects&#xD;
&#xD;
               1. Able to provide written and signed informed consent and any locally required&#xD;
                  authorization obtained from the subject/legal representative, which must be&#xD;
                  obtained prior to performing any protocol related procedures.&#xD;
&#xD;
               2. Men or women aged ≥18 years and ≤75 at the time of study entry.&#xD;
&#xD;
               3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or&#xD;
                  1.&#xD;
&#xD;
               4. Life expectancy ≥12 weeks.&#xD;
&#xD;
               5. Willing and able to comply with scheduled visits, treatment plan, laboratory&#xD;
                  tests, and other study procedures as specified in the protocol.&#xD;
&#xD;
               6. Subjects must provide the tumor tissue samples after the diagnosis of solid tumor&#xD;
                  or lymphoma.&#xD;
&#xD;
               7. Adequate organ function.&#xD;
&#xD;
               8. Subjects with Solid Tumors：Subjects must have a histologically or cytologically&#xD;
                  confirmed advanced solid tumor that is refractory or relapsed to the current&#xD;
                  standard therapies, or for which no effective standard therapy is available.&#xD;
                  Subject must have at least 1 measurable lesion according to RECIST v1.1.&#xD;
&#xD;
               9. Subjects with Lymphomas：Subjects must have histologically confirmed non-Hodgkin&#xD;
                  lymphoma(NHL), which may include transformed lymphoma, relapsed or refractory to&#xD;
                  autologous hematopoietic stem cell transplantation, or at least 2 lines of prior&#xD;
                  chemotherapy. Subjects must have disease that is measurable or assessable for&#xD;
                  response as per Lugano Classification 2014.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All Subjects&#xD;
&#xD;
               1. Concurrent enrollment in another clinical study, unless it is an observational&#xD;
                  clinical study or the follow up period of an interventional study.&#xD;
&#xD;
               2. Prior malignancy active within the previous 3 years except for the tumor for&#xD;
                  which a subject is enrolled in the study, and locally curable cancers that have&#xD;
                  been apparently cured.&#xD;
&#xD;
               3. Receipt: The last cycle of anticancer therapy within 3 weeks prior to the first&#xD;
                  dose of investigational product; Anticancer small molecule targeted agent,&#xD;
                  palliative local treatment for non-target lesions, non-specific immunomodulatory&#xD;
                  therapy within 2 weeks prior to the first dose of investigational product;&#xD;
                  Chinese medicines with anti-tumor indications within 1 week prior to the first&#xD;
                  dose of investigational product; Any major surgery within 4 weeks; RBC infusion&#xD;
                  within 3 months.&#xD;
&#xD;
               4. Metastasis or infiltration of brainstem and meninges;Metastasis or compression of&#xD;
                  the spinal cord; Active brain/central nervous system (CNS) metastases.&#xD;
&#xD;
               5. Subjects with clinical symptoms or repeated drainage of pleural effusion,&#xD;
                  pericardial effusion or ascites.&#xD;
&#xD;
               6. Cancer invasion of important surrounding organs or risk of esophageal tracheal&#xD;
                  fistula or esophageal pleural fistula.&#xD;
&#xD;
               7. Known history of testing positive for human immunodeficiency virus (HIV) or known&#xD;
                  active acquired immunodeficiency syndrome.&#xD;
&#xD;
               8. Known active hepatitis B or C infections (known positive HBsAg result or positive&#xD;
                  HCV antibody with detectable HCV ribonucleic acid [RNA] results).&#xD;
&#xD;
               9. Active or prior documented autoimmune disease that may relapse.&#xD;
&#xD;
              10. History of interstitial lung disease or noninfectious pneumonitis, except for&#xD;
                  those induced by radiation therapies.&#xD;
&#xD;
              11. History of hemolytic anemia of any cause within 3 months prior to the first dose&#xD;
                  of investigational product.&#xD;
&#xD;
              12. History of defects in RBC production, or hemoglobin production or&#xD;
                  metabolism.History of hemophagocytic lymphohistiocytosis.&#xD;
&#xD;
              13. Previous or current gastrointestinal perforation, surgical incision, wound&#xD;
                  healing complications and bleeding events.&#xD;
&#xD;
              14. Patients with clinically significant cardio-cerebrovascular disease.&#xD;
&#xD;
              15. Unresolved toxicities from prior anticancer therapy, defined as having not&#xD;
                  resolved to NCI CTCAE v5.0 Grade 0 or 1, or to levels dictated in the eligibility&#xD;
                  criteria with the exception of toxicities not considered a safety risk.&#xD;
&#xD;
              16. Subjects with a condition requiring systemic treatment with either&#xD;
                  corticosteroids or other immunosuppressive medications within 14 days prior to&#xD;
                  the first dose of investigational product.&#xD;
&#xD;
              17. Subjects with prior use of anti-PD-1, anti-PD-L1, anti-CTLA-4, or any other&#xD;
                  immuno-oncology agents, receipt of the following treatments or procedures: Use of&#xD;
                  immunotherapy or IO drug within 21 days prior to the first dose; Subjects had an&#xD;
                  irAE that resulted in permanent discontinuation of previous immunotherapy;&#xD;
                  Subjects had a history of grade 3 or higher irAE or cardiac, neurological, or&#xD;
                  ocular irAE of any grade at the time of prior immunotherapy; Prior to screening&#xD;
                  in this study, all AEs at the time of previous immunotherapy had not been&#xD;
                  completely remission or remission to grade 1; Subjects need to use other&#xD;
                  immunosuppressants other than glucocorticoids systematically to treat irAE.&#xD;
&#xD;
              18. History of severe hypersensitivity reactions to other mAbs.&#xD;
&#xD;
              19. History of organ transplantation.&#xD;
&#xD;
              20. Known allergy or reaction to any component of the investigational product&#xD;
                  formulation.&#xD;
&#xD;
              21. Receipt any anticancer therapy targeting the CD47/SIRPα signaling axis.&#xD;
&#xD;
              22. Known history of mental illness, alcohol or drug abuse.&#xD;
&#xD;
              23. Existing uncontrolled comorbiditions; Or a mental illness/social condition that&#xD;
                  may limit the subject's compliance with study requirements or affect the&#xD;
                  subject's ability to provide written informed consent.&#xD;
&#xD;
              24. Other exclusion criteria for subjects with lymphoma:History of HTLV-1&#xD;
                  infection.Subjects with primary or secondary central nervous system lymphoma.&#xD;
                  Subjects with history of allogeneic hematopoietic stem cell transplantation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiong Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weifeng Song, PhD</last_name>
    <phone>+86(0760)89873999</phone>
    <email>clinicaltrials@akesobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>FuDan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiong Wu, MD</last_name>
      <phone>021-64175590</phone>
      <email>Wujiong1122@vip.sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 24, 2021</study_first_submitted>
  <study_first_submitted_qc>January 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2021</study_first_posted>
  <last_update_submitted>January 24, 2021</last_update_submitted>
  <last_update_submitted_qc>January 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antineoplastic Agents, Immunological</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

